The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.

IF 4.7 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2025-07-09 DOI:10.1007/s11864-025-01335-3

Imperia Nuzzolese, Stefano Cavalieri, Lisa F Licitra, Salvatore Alfieri

{"title":"The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.","authors":"Imperia Nuzzolese, Stefano Cavalieri, Lisa F Licitra, Salvatore Alfieri","doi":"10.1007/s11864-025-01335-3","DOIUrl":null,"url":null,"abstract":"<p><p>Non-melanoma skin cancers (NMSCs), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in the Caucasian population. While localized disease has a high cure rate, advanced cases pose therapeutic challenges. The introduction of immune checkpoint inhibitors (ICIs) has revolutionized treatment; however, resistance and contraindications necessitate alternative strategies. Epidermal growth factor receptor (EGFR) inhibition, particularly with cetuximab, has emerged as a potential therapeutic option in cSCC. This review evaluates the role of cetuximab in NMSC, focusing on clinical efficacy, safety, and emerging therapeutic strategies. A literature search was conducted using PubMed and clinical trial databases to identify relevant studies on cetuximab in advanced cSCC and BCC. The review discusses its use as monotherapy, in combination with radiotherapy or chemotherapy, and in the post-ICI setting. Despite the dominance of ICIs in advanced cSCC, cetuximab remains a valuable option, particularly for patients with ICI failure or contraindications. Its role as a radiosensitizer and its potential combination with immunotherapy warrant further investigation. Future studies should clarify optimal sequencing and combination strategies to improve patient outcomes.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-025-01335-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Non-melanoma skin cancers (NMSCs), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in the Caucasian population. While localized disease has a high cure rate, advanced cases pose therapeutic challenges. The introduction of immune checkpoint inhibitors (ICIs) has revolutionized treatment; however, resistance and contraindications necessitate alternative strategies. Epidermal growth factor receptor (EGFR) inhibition, particularly with cetuximab, has emerged as a potential therapeutic option in cSCC. This review evaluates the role of cetuximab in NMSC, focusing on clinical efficacy, safety, and emerging therapeutic strategies. A literature search was conducted using PubMed and clinical trial databases to identify relevant studies on cetuximab in advanced cSCC and BCC. The review discusses its use as monotherapy, in combination with radiotherapy or chemotherapy, and in the post-ICI setting. Despite the dominance of ICIs in advanced cSCC, cetuximab remains a valuable option, particularly for patients with ICI failure or contraindications. Its role as a radiosensitizer and its potential combination with immunotherapy warrant further investigation. Future studies should clarify optimal sequencing and combination strategies to improve patient outcomes.

查看原文本刊更多论文

西妥昔单抗在非黑色素瘤皮肤癌中的作用：临床证据和新策略的回顾。

非黑色素瘤皮肤癌（NMSCs），特别是基底细胞癌（BCC）和皮肤鳞状细胞癌（cSCC），是高加索人群中最常见的恶性肿瘤。虽然局部疾病治愈率高，但晚期病例给治疗带来挑战。免疫检查点抑制剂（ICIs）的引入彻底改变了治疗方法；然而，抵抗和禁忌症需要替代策略。表皮生长因子受体（EGFR）抑制，特别是西妥昔单抗，已成为cSCC的潜在治疗选择。这篇综述评估了西妥昔单抗在NMSC中的作用，重点是临床疗效、安全性和新兴的治疗策略。通过PubMed和临床试验数据库进行文献检索，找出西妥昔单抗治疗晚期cSCC和BCC的相关研究。这篇综述讨论了它作为单一疗法、与放疗或化疗联合以及在ici后的应用。尽管ICI在晚期cSCC中占主导地位，西妥昔单抗仍然是一个有价值的选择，特别是对于ICI失败或有禁忌症的患者。它作为放射增敏剂的作用及其与免疫疗法的潜在结合值得进一步研究。未来的研究应阐明最佳的测序和联合策略，以改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.